Trial Profile
A Phase 0/II Study of Ceritinib (LDK378) in Preoperative Glioblastoma Multiforme (GBM) and CNS Metastasis Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Ceritinib (Primary)
- Indications Brain metastases; Breast cancer; Glioblastoma; Head and neck cancer; Malignant melanoma
- Focus Pharmacokinetics
- 26 Oct 2021 Results assessing tumor pharmacokinetics and tumor pharmacodynamics of ceritinib in patients with brain metastasis or recurrent glioblastoma published in the Clinical Cancer Research
- 10 Dec 2020 Status changed from active, no longer recruiting to completed.
- 15 Oct 2020 Planned End Date changed from 1 Sep 2020 to 1 Mar 2021.